Influence of obesity on urological malignancies;Der Einfluss von Adipositas auf urologische Tumorerkrankungen

Urologe - Ausgabe A

Volumn 52, Issue 9, 2013, Pages 1270-1275

  Eggers, H ^a   Kuczyk, M A ^a   Schrader, A J ^b   Steffens, S ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Metastases; Obesity; Overweight; Prostate cancer; Renal cell carcinoma

Indexed keywords

VASCULOTROPIN RECEPTOR;

ARTICLE; BLADDER CANCER; BODY MASS; CANCER GROWTH; HUMAN; KIDNEY CARCINOMA; KIDNEY SURGERY; OBESITY; OVERALL SURVIVAL; PHENOTYPE; PROSTATE CANCER; RISK FACTOR;

COMORBIDITY; EVIDENCE-BASED MEDICINE; HUMANS; OBESITY; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; UROLOGIC NEOPLASMS;

EID: 84884702290     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-013-3317-z     Document Type: Article

References (59)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638
2. Stewart SB, Freedland SJ (2011) Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol Oncol 29:476-486
3. MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17:989-1003
4. Fesinmeyer MD, Gulati R, Zeliadt S et al (2009) Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev 18:808-815
5. Gong Z, Neuhouser ML, Goodman PJ et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15:1977-1983
6. Rodriguez C, Freedland SJ, Deka A et al (2007) Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 16:63-69
7. Wright ME, Chang SC, Schatzkin A et al (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109:675-684
8. Buschemeyer WC 3rd, Freedland SJ (2007) Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52:331-343
9. Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88-97
10. Price MM, Hamilton RJ, Robertson CN et al (2008) Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology 71:787-791
11. Baillargeon J, Pollock BH, Kristal AR et al (2005) The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103:1092-1095
12. Barqawi AB, Golden BK, O'Donnell C et al (2005) Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 65:708-712
13. Fowke JH, Motley SS, Wills M et al (2007) Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes Control 18:375-384
14. Gray MA, Delahunt B, Fowles JR et al (2004) Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res 24:2069-2072
15. Ku JH, Kim ME, Lee NK et al (2003) Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 61:132-136
16. Werny DM, Thompson T, Saraiya M et al (2007) Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 16:70-76
17. Loeb S, Yu X, Nadler RB et al (2007) Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol 177:102-106 (discussion 106)
18. Hutterer G, Perrotte P, Gallina A et al (2007) Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. Eur J Cancer 43:1180-1187
19. Freedland SJ, Humphreys EB, Mangold LA et al (2006) Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176:1404-1408
20. Banez LL, Hamilton RJ, Partin AW et al (2007) Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298:2275-2280
21. Dahle SE, Chokkalingam AP, Gao YT et al (2002) Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168:599-604
22. Freedland SJ, Platz EA, Presti JC Jr et al (2006) Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 175:500-504
23. Kranse R, Beemsterboer P, Rietbergen J et al (1999) Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 39:316-322
24. Lowrance WT, Thompson RH, Yee DS et al (2010) Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int 105:16-20
25. Chow WH, McLaughlin JK, Mandel JS et al (1996) Obesity and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev 5:17-21
26. Lindblad P, Wolk A, Bergstrom R et al (1994) The role of obesity and weight fluctuations in the etiology of renal cell cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 3:631-639
27. Bergstrom A, Hsieh CC, Lindblad P et al (2001) Obesity and renal cell cancer-a quantitative review. Br J Cancer 85:984-990
28. Bjorge T, Tretli S, Engeland A (2004) Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol 160:1168-1176
29. Setiawan VW, Stram DO, Nomura AM et al (2007) Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 166:932-940
30. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev 4:579-591
31. Waalkes S, Merseburger AS, Kramer MW et al (2010) Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control 21:1905-1910
32. Waalkes S, Eggers H, Rustemeier J et al (2011) Overweight is an advantageous prognostic marker in patients with clear cell kidney cancer. Urologe A 50(9):1184-1124
33. Kamat AM, Shock RP, Naya Y et al (2004) Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63:46-50
34. Yu ML, Asal NR, Geyer JR (1991) Later recurrence and longer survival among obese patients with renal cell carcinoma. Cancer 68:1648-1655
35. Steffens S, Grünwald V, Ringe KI et al (2011) Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist 16(11):1565-1571
36. Golka K, Seidel T, Dietrich H et al (2005) Occupational and non-occupational risk factors in bladder cancer patients in an industrialized area located in former East-Germany. Aktuelle Urol 36:417-422
37. Koebnick C, Michaud D, Moore SC et al (2008) Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 17:1214-1221
38. Holick CN, Giovannucci EL, Stampfer MJ, Michaud DS (2007) Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer 120:140-146
39. Maurer T, Maurer J, Retz M et al (2009) Influence of body mass index on operability, morbidity and disease outcome following radical cystectomy. Urol Int 82:432-439
40. Chang SS, Jacobs B, Wells N et al (2004) Increased body mass index predicts increased blood loss during radical cystectomy. J Urol 171:1077-1079
41. Steffens S, Ringe KI, Schroeer K et al (2012) Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study. Int J Urol 20(6):585-592
42. Liao LM, Schwartz K, Pollak M (2012) Serum leptin and adiponectin levels and risk of renal cell carcinoma. Obesity (Silver Spring). doi: 10.1002/oby.20138
43. Bosetti C, Bertuccio P, Chatenoud L et al (2011) Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol 60(1):1-15
44. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and moratlity patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374-1403
45. Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 4:486-501
46. Allott EH, Masko EM, Freedland SJ (2013) Obesity and prostate cancer: weighing the evidence. Eur Urol 63(5):800-809. doi:10.1016/j.eururo
47. Keto CJ, Aronson WJ, Terris MK et al (2011) Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int 110:492-498
48. Schnoeller T, Jentzmik F, Rinnab L et al (2013) Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol 31:253-259
49. Lee G, Oh W (2009) Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 73:356-361
50. Roddam AW, Allen NE, Appleby P et al (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149:461-471
51. Saglam K, Aydur E, Yilmaz M, Goktas S (2003) Leptin influences cellular differentiation and progression in prostate cancer. J Urol 169:1308-1311
52. Amling CL (2005) Relationship between obesity and prostate cancer. Curr Opin Urol 15:167-171
53. Greenberg AS, Obin MS (2006) Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83:461-465
54. Nelson WB, De Marzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172:6-11
55. De Marzo AM, Platz EA, Sutcliffe S et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269
56. Rebbeck TR, Rennert H, Walker AH et al (2008) Joint effects of inflammation and androgen metabolism on prostate cancer severity. Int J Cancer 123:1385-1389
57. Spyridopoulos TN, Petridou ET, Dessypris N et al (2009) Inverse association of leptin levels with renal cell carcinoma: results from a case-control study. Hormones (Athens) 8(1):39-46
58. Lee CT, Dunn RL, Chen BT et al (2004) Impact of body mass index on radical cystectomy. J Urol 172(4 Pt 1):1281-1285
59. Bagrodia A, Grover S, Srivastava A et al (2009) Impact of body mass index on clinical and cost outcomes after radical cystectomy. BJU Int 104(3):326-330